Turkey Tail Segment 1 part three Advocacy for Mushroom Vape

214 records selected for initial screening for efficacy in
Lung Cancer articles
167 records excluded after deduplication and initial title/ abstract review
47 full text articles screened
16 records excluded
- 3 Reviews
- 13 Not relevant to PSK and lung cancer, not related to treatment effects, non-English preclinical studies, or a duplication of data
31 Articles included for Data Extraction and Analysis
- 15 Reports of 11 controlled human trials
- 7 reports of 6 RCTs
- 8 reports of 5 non-randomized controlled trials
- O Observational Studies
- 17 Preclinical studies (1 included in RCT report)

Survival
One of two randomized controlled trials assessing survival endpoints demonstrated statistically significant results.19,24 Ikeda et al19 found that PSK significantly increased 1-year survival compared with chemotherapy alone, 88.9% compared with 61.8% (P < .05). Neither of the two studies found significant effects on overall median survival, though Ikeda et al19 found significantly increased median survival among patients with stage 1 disease (P < .001).

Advocacy for Mushroom Vape

Safety and Risks Associated With Use
No major adverse effects were reported in the studies reviewed above, including when PSK was administered to patients as long-term adjuvant therapy at a dose of 3 g daily for five or more years.17 There are no known contraindications for use during chemotherapy or radiation therapy. Coriolus has not been reported to affect clotting times. Some studies have reported no effect on platelet counts, while some report PSK offsetting the postchemotherapy decrease in platelets; however, there have been no reports of PSK decreasing platelet counts.14,15,21,28Coriolus extracts may shorten or reduce the degree of immunosuppression associated with chemotherapy, without deleterious effects on liver or kidney function.17,28

Advocacy for mushroom Vape